I wanted to share my GOOD feelings with my awesome YouTube family, after my 2 recent “downer” videos!
Video Rating: 5 / 5
Going for my MRI. Dealing with my Copaxone shots, and symptons of MS. A little self promotion for my MS related Facebook pages.
Video Rating: 5 / 5
Updates on my MS
I recently had a MRI (I get one every 6 months) and there were NO NEW LESIONS OR DISEASE ACTIVITY.
UBC continues with research on CCSVI. The attached video shows “Time Resolved MRI Venography/Angiography” in a person with MS. The images were recently acquired with the UBC MRI Research Centre’s 3T MRI scanner using a new technique called 4D TRAK. Dr. Zamboni spoke of time resolved angiography as a potential future technique in CCSVI in one of his papers (Singh and Zamboni, 2009). The future is here! You can clearly see how the left jugular vein drainage is delayed by several seconds. Thank you UBC MRI Research Centre!
Video Rating: 5 / 5
My “Storm” Living with MS DIAGNOSIS OF MS MRI ACCEPTANCE OF DESEASE BEING IN THE HOSPITAL
My most recent MRI has been the same as all the others since I started Tysabri in November of 2006: Stable.
I wanted to share my GOOD feelings with my awesome YouTube family, after my 2 recent “downer” videos!
August update Part II
I have had MS for well over 5 years now. Rebif helped me for three years (my relapses went from 4 ayear to two, and they were much milder). However, my MS has sped up again, so I am going to start Tysabri….
just a quick update on my happenings for the last month or so… and to also recommend “Momentum” written by the National Multiple Sclerosis Society… PS… shout out & congrats to deborahdaugter7 on the new pregnancy!
Update on Tysabri and PML: Company Releases Details of Cases and Risks According to information released on October 29, 2009 by Biogen Idec, there have been 24 confirmed cases of progressive multifocal leukoencephalopathy (PML, a viral infection of the brain that usually leads to death or severe disability) among people who have used Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) after it became available for prescription in July 2006. As of the end of September 2009, 60700 people have used Tysabri worldwide. Although the absolute risk for PML in patients treated with Tysabri cannot be precisely determined, the sponsor has now released data suggesting that the risk increases with increasing time on therapy, starting out lower than the one-in-one thousand level that was estimated at the time of Tysabris re-approval in 2006, and rising after two years of infusions to about one in one thousand. There is insufficient information to determine the risk of PML in those who have been on therapy for three years or more. Right now only 2000 people have been on the therapy for over three years. This release followed an October 23 announcement from the EMEA, the European equivalent of the US FDA, indicating that one of its advisory committees was launching a review of the risks and benefits of Tysabri in light of the increasing number of new cases of PML. Signs of PML: Typical symptoms associated with PML progress quickly over days to weeks, and can include …